Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
暂无分享,去创建一个
Maurice Buchbinder | M. Buchbinder | V. Reddy | D. Holmes | P. Sick | H. Sievert | Z. Turi | Vivek Y Reddy | David R Holmes | Peter Sick | Horst Sievert | Christopher M Mullin | Zoltan G Turi | Shephal K Doshi | S. Doshi | C. Mullin
[1] John K Kruschke,et al. Bayesian data analysis. , 2010, Wiley interdisciplinary reviews. Cognitive science.
[2] William H. Maisel,et al. Left atrial appendage occlusion--closure or just the beginning? , 2009, The New England journal of medicine.
[3] S. Haas. New anticoagulants - towards the development of an "ideal" anticoagulant. , 2009, VASA. Zeitschrift fur Gefasskrankheiten.
[4] S. Lerakis,et al. Left atrial appendage exclusion system for stroke prevention in atrial fibrillation: a percutaneous device delivery approach. , 2008, Minerva Cardioangiologica : a Journal on Cardiovascular Pathophysiology, Clinical Medicine and Therapy.
[5] A. Walker,et al. Epidemiology and outcomes in patients with atrial fibrillation in the United States. , 2008, Heart rhythm.
[6] E. Hylek,et al. Reducing the risk for stroke in patients who have atrial fibrillation. , 2008, Cardiology clinics.
[7] H. Klemm,et al. Mechanisms underlying air aspiration in patients undergoing left atrial catheterization , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[8] S. Yusuf,et al. Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation , 2007, Circulation.
[9] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[10] D. Berman,et al. Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.
[11] G. Schuler,et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. , 2007, Journal of the American College of Cardiology.
[12] P. Block,et al. Clinical outcomes three years after PLAATO implantation , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[13] A. Kalogeropoulos,et al. Implantation of Left Atrial Appendage Occlusion Devices and Complex Appendage Anatomy: The Importance of Transesophageal Echocardiography , 2007, Echocardiography.
[14] O. Onalan,et al. Left Atrial Appendage Exclusion for Stroke Prevention in Patients With Nonrheumatic Atrial Fibrillation , 2007, Stroke.
[15] D. Sherman. Stroke Prevention in Atrial Fibrillation: Pharmacological Rate Versus Rhythm Control , 2007, Stroke.
[16] Stephen S. Cha,et al. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.
[17] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[18] D. Packer,et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. , 2006, American heart journal.
[19] Jerry Nedelman,et al. Book review: “Bayesian Data Analysis,” Second Edition by A. Gelman, J.B. Carlin, H.S. Stern, and D.B. Rubin Chapman & Hall/CRC, 2004 , 2005, Comput. Stat..
[20] E. Kaufman,et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. , 2005, Archives of internal medicine.
[21] H. Ashraf. Anticoagulation therapy for stroke. , 2005, Drug discovery today.
[22] P. Teirstein,et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. , 2005, Journal of the American College of Cardiology.
[23] Palle Petersen,et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. , 2005, JAMA.
[24] G. Albers. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. , 2004, The American journal of managed care.
[25] J. Hirsh,et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[26] D. Levy,et al. Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.
[27] Randolph P. Martin,et al. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. , 2004, Journal of the American College of Cardiology.
[28] J. Finsterer,et al. Elimination of the left atrial appendage to prevent stroke or embolism? Anatomic, physiologic, and pathophysiologic considerations. , 2003, Chest.
[29] Yuchiao Chang,et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.
[30] S. Olsson,et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.
[31] H. Crijns,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.
[32] H. Crijns,et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .
[33] A L Waldo,et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.
[34] M. Lesh,et al. Percutaneous Left Atrial Appendage Transcatheter Occlusion to Prevent Stroke in High-Risk Patients With Atrial Fibrillation: Early Clinical Experience , 2002, Circulation.
[35] Ana Ruigómez,et al. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. , 2002, Journal of clinical epidemiology.
[36] J. Coste,et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. , 2001, The New England journal of medicine.
[37] J. McMurray,et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study , 2001, Heart.
[38] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[39] M. Rich,et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. , 2000, Stroke.
[40] D. Singer,et al. Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.
[41] L H Kuller,et al. Incidence of and risk factors for atrial fibrillation in older adults. , 1997, Circulation.
[42] Strokepreventioninatrialfibri. The stroke prevention in atrial fibrillation III study: rationale, design, and patient features. , 1997, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[43] R B D'Agostino,et al. Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.
[44] J. Odell,et al. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.
[45] P. Koudstaal. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. , 1995, The New England journal of medicine.
[46] N. Ammash,et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographics tudy , 1995 .
[47] D. Levy,et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. , 1994, JAMA.
[48] H. White,et al. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .
[49] M. Ezekowitz,et al. Stroke Prevention in Atrial Fibrillation II Study. , 1994, Lancet.
[50] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[51] Leandro Provinciali,et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .
[52] S M Nazarian,et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.
[53] M Gent,et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.
[54] P. Wolf,et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.
[55] Lippincott Williams Wilkins,et al. Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.
[56] Bernard Rosner,et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.
[57] D. Anderson,et al. Progress report of the Stroke Prevention in Atrial Fibrillation Study. , 1990, Stroke.
[58] Palle Petersen,et al. PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.
[59] Z. J. Lipowski. Letter: Psychosomatic medicine. , 1974, Lancet.
[60] H. Aberg. Atrial fibrillation. I. A study of atrial thrombosis and systemic embolism in a necropsy material. , 2009, Acta medica Scandinavica.